CTEV

+ Watchlist + Portfolio

Claritev Corp.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $35.39
52-Week Range: $11.50 – $74.07
Market Cap: $577.57M
P/E (TTM): —
EPS (TTM): -17.00
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: 1.19%
Gross Margin: 72.97%
Operating Margin: 12.80%
Profit Margin: -28.46%
Current Ratio: 0.99
Debt/Equity: —
Total Debt: $4.69B
Free Cash Flow: $102.99M
Revenue Growth: 6.60%
Earnings Growth: —
Enterprise Value: $5.29B

CTEV Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.08B	$961.52M	$930.62M	$965.41M
Cost of Revenue	$204.10M	$295.62M	$303.45M	$316.37M
Gross Profit	$875.62M	$665.90M	$627.17M	$649.05M
Selling, General & Admin	$132.14M	$74.97M	$86.84M	$158.56M
Operating Expenses	$541.44M	$494.98M	$518.92M	$603.99M
Operating Income	$334.18M	$170.92M	$108.26M	$45.06M
EBITDA	$158.32M	$651.93M	-$1.01B	$467.40M
Pretax Income	-$560.74M	-$107.06M	-$1.77B	-$373.08M
Income Tax	$12.17M	-$15.36M	-$124.88M	-$88.80M
Net Income	-$572.91M	-$91.70M	-$1.65B	-$284.28M
Diluted EPS	-36.00	-5.69	-101.92	-17.30
Diluted Shares	15.97M	16.13M	16.15M	16.43M

CTEV Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$334.05M	$71.55M	$16.85M	$16.81M
Receivables	$78.91M	$84.75M	$111.61M	$138.18M
Current Assets	$446.74M	$193.59M	$175.51M	$224.37M
Total Assets	$7.37B	$6.96B	$5.15B	$4.89B
Current Liabilities	$175.84M	$166.74M	$213.79M	$261.36M
Long-Term Debt	$4.74B	$4.53B	$4.51B	$4.58B
Total Debt	$4.78B	$4.57B	$4.54B	$4.62B
Total Liabilities	$5.58B	$5.26B	$5.07B	$5.06B
Retained Earnings	-$347.80M	-$499.31M	-$2.15B	-$2.43B
Shareholders' Equity	$1.79B	$1.71B	$84.02M	-$173.90M
Working Capital	$270.89M	$26.85M	-$38.27M	-$36.99M
Net Debt	$4.42B	$4.47B	$4.51B	$4.58B

CTEV Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$372.36M	$171.72M	$107.62M	$117.32M
Capital Expenditure	-$89.73M	-$108.85M	-$118.12M	-$129.60M
Free Cash Flow	$282.63M	$62.87M	-$10.51M	-$12.28M
Depreciation & Amortisation	$415.66M	$425.79M	$436.44M	$448.45M
Stock-Based Compensation	$16.74M	$18.02M	$26.64M	$27.82M
Investing Cash Flow	-$104.45M	-$249.79M	-$118.12M	-$121.02M
Financing Cash Flow	-$115.74M	-$180.99M	-$41.31M	$2.36M
Share Repurchases	$0.00	-$15.22M	-$10.37M	$0.00
Net Change in Cash	$152.18M	-$259.06M	-$51.82M	-$1.33M

CTEV Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$231.33M	$241.57M	$245.96M	$246.55M	$244.68M
Cost of Revenue	$77.20M	$79.13M	$82.31M	$78.03M	$80.81M
Gross Profit	$154.13M	$162.44M	$163.65M	$168.52M	$163.87M
Selling, General & Admin	$30.20M	$34.63M	$41.65M	$48.11M	$46.10M
Operating Expenses	$140.72M	$145.86M	$153.59M	$159.85M	$157.19M
Operating Income	$13.41M	$16.58M	$10.07M	$8.67M	$6.68M
EBITDA	$113.31M	$128.83M	$120.49M	$104.77M	$118.47M
Pretax Income	-$89.87M	-$82.93M	-$93.36M	-$106.92M	-$92.72M
Income Tax	-$18.55M	-$20.29M	-$23.61M	-$26.35M	-$19.16M
Net Income	-$71.32M	-$62.64M	-$69.75M	-$80.57M	-$73.56M
Diluted EPS	-4.38	-3.81	-4.23	-4.88	-4.41
Diluted Shares	16.27M	16.45M	16.48M	16.53M	16.69M

CTEV Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$23.13M	$56.39M	$39.15M	$16.81M	$21.33M
Receivables	$116.58M	$142.57M	$142.35M	$138.18M	$154.22M
Current Assets	$184.84M	$247.14M	$257.46M	$224.37M	$242.27M
Total Assets	$5.08B	$5.07B	$4.99B	$4.89B	$4.84B
Current Liabilities	$180.47M	$253.14M	$213.32M	$261.36M	$189.56M
Long-Term Debt	$4.60B	$4.61B	$4.62B	$4.58B	$4.70B
Total Debt	$4.63B	$4.65B	$4.65B	$4.62B	$4.73B
Total Liabilities	$5.07B	$5.11B	$5.09B	$5.06B	$5.07B
Retained Earnings	-$2.22B	-$2.28B	-$2.35B	-$2.43B	-$2.50B
Shareholders' Equity	$14.82M	-$39.91M	-$101.83M	-$173.90M	-$241.14M
Working Capital	$4.36M	-$6.00M	$44.14M	-$36.99M	$52.70M
Net Debt	$4.59B	$4.57B	$4.59B	$4.58B	$4.69B

CTEV Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$30.06M	$61.24M	$19.86M	$66.29M	-$45.78M
Capital Expenditure	-$38.87M	-$24.62M	-$36.20M	-$29.91M	-$46.77M
Free Cash Flow	-$68.92M	$36.61M	-$16.35M	$36.38M	-$92.55M
Depreciation & Amortisation	$111.54M	$112.02M	$112.62M	$112.28M	$111.65M
Stock-Based Compensation	$6.33M	$6.71M	$6.99M	$7.80M	$6.89M
Investing Cash Flow	-$38.87M	-$24.62M	-$22.87M	-$34.66M	-$46.77M
Financing Cash Flow	$73.15M	-$3.23M	-$13.63M	-$53.93M	$98.93M
Share Repurchases	$0.00	$0.00	$0.00	$0.00	—
Net Change in Cash	$4.23M	$33.39M	-$16.64M	-$22.30M	$6.39M

Market Snapshot

About

Claritev Corp. is a medical technology company focused on developing innovative surgical products for the treatment of ear, nose, and throat conditions. Headquartered in Eden Prairie, Minnesota, the company specializes in devices for chronic sinusitis and other ENT disorders, with its flagship product being a proprietary balloon sinus dilation system. Claritev's technology is designed to provide minimally invasive treatment options that can be performed in physician offices rather than hospital operating rooms. The company aims to improve patient outcomes while reducing healthcare costs through its point-of-care solutions.